Head and neck neoplasm
MONDO:0005586A benign or malignant neoplasm that affects the anatomic structures of the head and neck region. Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma. Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
Also known as: craniocervical region neoplasm, craniocervical region neoplasm (disease), craniocervical region tumor, craniocervical region tumour, head and neck neoplasm, head and neck neoplasm (excluding central nervous system), head and neck tumor, head and neck tumour
3518 clinical trials for this condition and its sub-types, 79 tagged with Head and neck neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Head and neck neoplasm
-
Head and neck cancer 638 trials · 2,010 incl. sub-types
16 sub-types
- Head and neck carcinoma 74 trials · 1,420 incl. sub-types Sub-types →
- Malignant tumor of neck 14 trials · 507 incl. sub-types Sub-types →
- Ocular cancer 10 trials · 168 incl. sub-types Sub-types →
- Salivary gland cancer 62 trials · 81 incl. sub-types Sub-types →
- Skull cancer 0 trials · 38 incl. sub-types Sub-types →
- Tongue cancer 26 trials · 35 incl. sub-types Sub-types →
- Lip cancer 12 trials · 15 incl. sub-types Sub-types →
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Malignant cranial nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Cheek mucosa cancer 1 trial · 2 incl. sub-types Sub-types →
- Gingival cancer 1 trial · 2 incl. sub-types Sub-types →
- Malignant ear neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Malignant tumor of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Hard palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Angiosarcoma of the scalp 0 trials
- Malignant carotid body paraganglioma 0 trials
-
Neoplasm of neck 1 trial · 507 incl. sub-types
4 sub-types
- Malignant tumor of neck 14 trials · 507 incl. sub-types Sub-types →
- Benign neoplasm of neck 0 trials
- Cervical dermoid cyst 0 trials
- Cervical neuroblastoma 0 trials
-
Neoplasm of oropharynx 3 trials · 280 incl. sub-types
2 sub-types
- Oropharynx cancer 150 trials · 280 incl. sub-types Sub-types →
- Benign neoplasm of oropharynx 0 trials
-
Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types
3 sub-types
- Malignant tumor of nasopharynx 9 trials · 214 incl. sub-types Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Nasopharyngeal teratoma 0 trials
-
Eye neoplasm 3 trials · 192 incl. sub-types
13 sub-types
- Ocular cancer 10 trials · 168 incl. sub-types Sub-types →
- Uvea neoplasm 1 trial · 103 incl. sub-types Sub-types →
- Retina neoplasm 2 trials · 36 incl. sub-types Sub-types →
- Conjunctival tumor 1 trial · 23 incl. sub-types Sub-types →
- Benign neoplasm of eye 0 trials · 19 incl. sub-types Sub-types →
- Cornea neoplasm 0 trials · 17 incl. sub-types Sub-types →
- Eyelid neoplasm 3 trials · 7 incl. sub-types Sub-types →
- Intraocular medulloepithelioma 1 trial
- Ocular surface squamous neoplasia 1 trial
- Combined hamartoma of the retina and retinal pigment epithelium 0 trials
- Lacrimal gland neoplasm 0 trials Sub-types →
- Orbital leiomyoma 0 trials
- Ring dermoid of cornea 0 trials
-
Skull neoplasm 0 trials · 161 incl. sub-types
7 sub-types
- Skull base neoplasm 12 trials · 124 incl. sub-types Sub-types →
- Skull cancer 0 trials · 38 incl. sub-types Sub-types →
- Paranasal sinus neoplasm 5 trials · 29 incl. sub-types Sub-types →
- Neoplasm of jaw 1 trial · 9 incl. sub-types Sub-types →
- Orbit neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Jugular foramen meningioma 0 trials
- Schwannoma of jugular foramen 0 trials
-
Neoplasm of hypopharynx 0 trials · 100 incl. sub-types
3 sub-types
- Hypopharynx cancer 50 trials · 100 incl. sub-types Sub-types →
- Benign neoplasm of hypopharynx 0 trials Sub-types →
- Epiglottis neoplasm 0 trials Sub-types →
-
Tumor of salivary gland 9 trials · 85 incl. sub-types
4 sub-types
- Salivary gland cancer 62 trials · 81 incl. sub-types Sub-types →
- Neoplasm of major salivary gland 0 trials · 17 incl. sub-types Sub-types →
- Benign neoplasm of salivary gland 1 trial · 5 incl. sub-types Sub-types →
- Neoplasm of minor salivary gland 0 trials Sub-types →
-
Nasal cavity and paranasal sinus neoplasm 0 trials · 44 incl. sub-types
1 sub-type
- Nasal cavity and paranasal sinus carcinoma 21 trials · 44 incl. sub-types Sub-types →
-
Tongue neoplasm 2 trials · 35 incl. sub-types
2 sub-types
- Tongue cancer 26 trials · 35 incl. sub-types Sub-types →
- Benign neoplasm of tongue 0 trials
-
Lip neoplasm 1 trial · 15 incl. sub-types
2 sub-types
- Lip cancer 12 trials · 15 incl. sub-types Sub-types →
- Benign neoplasm of lip 0 trials
-
Nasal cavity neoplasm 1 trial · 15 incl. sub-types
3 sub-types
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Nasal cavity inverting papilloma 0 trials
-
Benign epithelial tumor of salivary glands 0 trials · 12 incl. sub-types
1 sub-type
- Pleomorphic adenoma 12 trials
-
Recurrent respiratory papillomatosis 8 trials · 9 incl. sub-types
1 sub-type
- Laryngeal papillomatosis 1 trial
-
Cranial nerve neoplasm 0 trials · 8 incl. sub-types
12 sub-types
- Malignant cranial nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Olfactory nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Optic nerve neoplasm 1 trial · 4 incl. sub-types Sub-types →
- Abducens nerve neoplasm 0 trials
- Facial nerve neoplasm 0 trials
- Glossopharyngeal nerve neoplasm 0 trials Sub-types →
- Hypoglossal nerve neoplasm 0 trials Sub-types →
- Oculomotor nerve neoplasm 0 trials Sub-types →
- Spinal accessory nerve neoplasm 0 trials
- Trigeminal nerve neoplasm 0 trials Sub-types →
- Trochlear nerve neoplasm 0 trials
- Vestibulocochlear nerve neoplasm 0 trials Sub-types →
-
Tonsil neoplasm 0 trials · 8 incl. sub-types
2 sub-types
- Tonsil cancer 5 trials · 8 incl. sub-types Sub-types →
- Benign neoplasm of tonsil 0 trials Sub-types →
-
Odontogenic neoplasm 0 trials · 5 incl. sub-types
4 sub-types
- Keratocystic odontogenic tumor 3 trials
- Ameloblastoma 2 trials Sub-types →
- Ameloblastic carcinoma 0 trials
- Calcifying epithelial odontogenic tumor 0 trials
-
Ocular adnexal lymphoma 4 trials
-
Malignant epithelial tumor of salivary glands 0 trials · 4 incl. sub-types
1 sub-type
-
Ear neoplasm 0 trials · 3 incl. sub-types
5 sub-types
- Malignant ear neoplasm 0 trials · 2 incl. sub-types Sub-types →
- External ear neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Inner ear neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Neoplasm of middle ear 0 trials · 1 incl. sub-types Sub-types →
- Benign neoplasm of ear 0 trials Sub-types →
-
Familial thyroglossal duct cyst 2 trials
-
Buccal mucosa neoplasm 0 trials · 2 incl. sub-types
2 sub-types
- Cheek mucosa cancer 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of buccal mucosa 0 trials Sub-types →
-
Gingival neoplasm 0 trials · 2 incl. sub-types
3 sub-types
- Gingival cancer 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of gum 0 trials Sub-types →
- Congenital epulis 0 trials
-
Neoplasm of floor of mouth 0 trials · 2 incl. sub-types
2 sub-types
- Malignant tumor of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Benign neoplasm of floor of mouth 0 trials
-
Palatal neoplasm 0 trials · 2 incl. sub-types
4 sub-types
- Hard palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Soft palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Benign neoplasm of hard palate 0 trials
- Benign neoplasm of soft palate 0 trials
-
Head and neck paraganglioma 1 trial
4 sub-types
- Carotid body paraganglioma 0 trials Sub-types →
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Tympanic paraganglioma 0 trials
- Vagus nerve paraganglioma 0 trials
-
Cavernous hemangioma of face 0 trials
1 sub-type
- Cavernous hemangioma of retina 0 trials
-
Epignathus 0 trials
-
Facial dermoid cyst 0 trials
2 sub-types
- Nasal dermoid cyst 0 trials
- Orbital dermoid cyst 0 trials
-
Gasserian ganglion meningioma 0 trials
-
Laryngeal neuroendocrine neoplasm 0 trials
1 sub-type
- Laryngeal small cell carcinoma 0 trials
-
Laryngotracheal angioma 0 trials
-
Lipoma of face 0 trials
1 sub-type
- Lipoma of the conjunctiva 0 trials
-
Nasal ganglioglioma 0 trials
-
Nasal glial heterotopia 0 trials
Most studied deeper sub-types
-
Can immunotherapy before surgery stop early oral cancer from returning?
Cure Not yet recruitingThis phase 3 trial tests whether adding sintilimab, an immunotherapy drug, to chemotherapy before surgery helps people with early-stage oral squamous cell carcinoma. Participants are adults aged 18 to 75 with cT2N0M0 oral cancer that can be removed by surgery. Half receive sintil…
Phase 3 • Sponsor: caohaotian • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Can your own immune cells fight advanced cancer?
Cure Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Can a Two-Drug punch shrink oral tumors before surgery?
Cure Not yet recruitingThis phase 2 trial is testing whether giving two drugs before surgery can help people with advanced oral cavity cancer. The drugs, becotatug vedotin and pucotenlimab, are designed to attack cancer cells and boost the immune system. Participants receive three cycles of the combina…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill restore the Body's tumor suppressor to fight multiple cancers?
Cure Not yet recruitingThis trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…
Phase 1/2 • Sponsor: LG Chem • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Can a triple therapy shrink head and neck tumors before surgery?
Cure Not yet recruitingThis phase 2 trial is testing whether a new drug called RiMO-301, given alongside radiation and the immunotherapy pembrolizumab (Keytruda), can shrink tumors before surgery in people with resectable, locally advanced head and neck cancer. The study will measure how many patients'…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
Custom-Made cancer vaccine enters early human testing
Vaccine Not yet recruitingThis study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …
Early phase 1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New injectable drug tested for safety in Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a phase 1 trial of SHR-4595, an experimental injectable drug, in adults with advanced solid tumors that have not responded to standard treatments. The study checks how safe and tolerable the drug is, how the body processes it, and what dose might work best…
Phase 1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?
Disease control Not yet recruitingThis phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?
Disease control Not yet recruitingResearchers are testing whether adding CT-guided thermal ablation of liver or lung metastases to standard systemic therapy improves tumor response in people with nasopharyngeal carcinoma. The trial enrolls 138 adults whose primary tumor was cured but who later developed up to fiv…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug combo shrink High-Risk throat tumors?
Disease control Not yet recruitingThis phase II trial tests whether the experimental drug BL-B01D1, given with or without a PD-1 antibody, can improve tumor shrinkage in people with high-risk locally advanced nasopharyngeal carcinoma, a type of throat cancer. Participants also receive standard chemotherapy drugs …
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug combo keep advanced nasopharyngeal cancer at bay?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called BL-B01D1 to standard maintenance therapy with a PD-1 antibody can help people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer progressing. Participants first receive …
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Radiation plus targeted antibody tested in older head and neck cancer patients
Disease control Not yet recruitingResearchers are testing whether adding nimotuzumab to intensity-modulated radiation therapy helps older adults with locally advanced head and neck squamous cell carcinoma who cannot tolerate standard chemotherapy. The study enrolls patients aged 65 and older with EGFR-positive tu…
Phase 2 • Sponsor: Ke Hu • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental infusion drug tested against recurrent nasopharyngeal cancer
Disease control Not yet recruitingResearchers are testing an experimental drug called BL-M08D1 in adults with nasopharyngeal carcinoma that has come back or spread, as well as other solid tumors. Participants receive the drug by intravenous infusion every three weeks. The trial aims to find a safe dose for furthe…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Cataract lens under the microscope: does it stay put?
Disease control Not yet recruitingResearchers are studying how stable the RayOne RAO800S intraocular lens is after cataract surgery. The lens replaces the eye's cloudy natural lens and has marks to help surgeons position it. Adults scheduled for cataract surgery in both eyes receive the lens as part of routine ca…
Sponsor: Rayner Intraocular Lenses Limited • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Blood test could guide cancer treatment, reducing side effects
Disease control Not yet recruitingThis study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a migraine drug make oral cancer treatment hit harder?
Disease control Not yet recruitingResearchers are testing whether adding rimegepant to standard chemoimmunotherapy before surgery helps shrink oral or oropharyngeal squamous cell carcinoma more effectively. The trial enrolls adults with primary or recurrent disease who are scheduled for surgery. Participants rece…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a guided missile for chemo hit tumors harder and spare healthy tissue?
Disease control Not yet recruitingResearchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…
Phase 1 • Sponsor: TwoStep Therapeutics, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a stronger radiation dose fix hormone overload?
Disease control Not yet recruitingResearchers are testing whether a higher dose of proton beam therapy can normalise hormone levels better than standard radiotherapy in people with functioning pituitary tumours, including acromegaly and Cushing's disease. Participants receive about six weeks of either standard-do…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Liver-Targeted immune cell attack tested against melanoma spread
Disease control Not yet recruitingResearchers are testing a treatment for melanoma that has spread to the liver. They collect tumor-infiltrating lymphocytes, a type of immune cell, from the patient's own tumor and grow them in the lab. Before returning the cells, they use a technique called percutaneous hepatic p…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Immune cells injected into liver or veins to fight advanced melanoma
Disease control Not yet recruitingThis early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with che…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase 4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shrink tumors that resist standard care?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…
Phase 1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Triple-Drug cocktail aims to shrink head and neck tumors
Disease control Not yet recruitingThis study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…
Phase 3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a primer drug make chemotherapy work better for frail head and neck cancer patients?
Disease control Not yet recruitingThis phase 2 trial tests whether giving toripalimab first can prime head and neck cancer tumors to respond better to the chemotherapy drug paclitaxel. The study enrolls 22 patients with metastatic or incurable head and neck squamous cell carcinoma who have a reduced performance s…
Phase 2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to shrink oral tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery to people with a type of oral cancer that is HPV-negative and can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before the operation. Abo…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Platinum-Free regimen beat nasopharyngeal carcinoma?
Disease control Not yet recruitingThis phase II trial tests a new treatment approach for people with locally advanced nasopharyngeal carcinoma, a type of head and neck cancer. The regimen avoids platinum-based chemotherapy, using a combination of gemcitabine, camrelizumab, endostar, and low-dose radiotherapy befo…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a smart chemo drug outsmart advanced throat cancer?
Disease control Not yet recruitingThis trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…
Phase 3 • Sponsor: Corbus Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug boost chemotherapy for head and neck cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called Enlituo to a standard chemotherapy combination helps people with advanced, recurrent, or metastatic head and neck squamous cell carcinoma. Participants receive either the standard combination (Anyouping plus platinum-bas…
Phase 2/3 • Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat head and neck tumors?
Disease control Not yet recruitingThis Phase II trial tests an experimental drug called BL-M08D1 in adults with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors. The drug is given by intravenous infusion every 3 weeks. Researchers will measure how well it shrinks tumors and how…
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a lower radiation dose still beat nasopharyngeal cancer?
Disease control Not yet recruitingThis trial tests whether people with early-stage nasopharyngeal cancer who respond well to induction chemotherapy can safely receive a lower dose of radiation than the standard. Participants whose tumors shrink significantly and whose EBV-DNA drops to zero after chemo are randoml…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Dual-Pronged antibody outsmart advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Long-Acting immune booster help fight advanced solid tumours?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental virus therapy takes on Drug-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill outsmart mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…
Phase 1 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Not yet recruitingThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Not yet recruitingThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a grid of proton beams boost immunotherapy against oral cancer?
Disease control Not yet recruitingThis phase II trial is testing whether adding a special type of radiation therapy to the immunotherapy drug pembrolizumab before surgery can help shrink oral cavity tumors. The study compares two radiation techniques: proton spatially fractionated radiotherapy (SFRT), which deliv…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can immune cells shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…
Phase 1 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can watching and waiting beat early treatment for Slow-Growing head and neck tumors?
Disease control Not yet recruitingThis trial asks whether monitoring a slow-growing head and neck tumor without immediate treatment can preserve quality of life better than early surgery or radiation. Adults with newly diagnosed carotid or vagal paragangliomas are randomly assigned to either active surveillance o…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn childhood cancers
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Cutting radiation after surgery: a new hope for head and neck cancer patients?
Disease control Not yet recruitingThis trial is testing whether giving a lower dose of radiation after surgery can be as effective as the standard dose for people with advanced head and neck cancer. Participants first receive chemotherapy and immunotherapy before surgery, and then the radiation plan is tailored b…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Two-Drug punch shrink oral tumors before surgery?
Disease control Not yet recruitingThis phase II trial is testing whether combining a TROP-2 antibody-drug conjugate (sacituzumab govitecan or sacituzumab tirumotecan) with the immunotherapy drug toripalimab can shrink tumors in people with resectable, locally advanced oral squamous cell carcinoma. Participants re…
Phase 2 • Sponsor: Shanghai East Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Three-Drug combo wipe out head and neck tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving a combination of two newer drugs—an immunotherapy called adebrelimab and a targeted therapy called dalpiciclib—along with standard chemotherapy (cisplatin) before surgery can improve outcomes for people with locally advanced head and neck canc…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can adding immunotherapy to standard care beat a tough head and neck cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an immunotherapy drug called tislelizumab to the standard treatment of chemotherapy and radiation can improve outcomes for people with advanced head and neck cancer that is not linked to HPV and cannot be removed with surgery. Particip…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Not yet recruitingThis phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Vein repair during cancer surgery may prevent disfiguring swelling
Disease control Not yet recruitingThis trial tests whether repairing the facial vein during neck dissection can prevent lymphedema—painful swelling—in adults with head and neck cancer. Participants receive standard cancer surgery plus, if needed, immediate reconstruction of the facial vein. Researchers then compa…
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Two punch of immunotherapy and radiation wipe out head and neck tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab with a short course of high-dose radiation, with or without additional radiation to nearby lymph nodes, can shrink or eliminate head and neck tumors before surgery. Adults with resectable squamou…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could avoiding Pre-Radiation tooth removal protect jaw health?
Disease control Not yet recruitingThis trial asks whether it is safe to skip the routine removal of impacted teeth before radiation therapy for nasopharyngeal carcinoma. Half of the participants will have the extraction as usual, while the other half will not. The study will compare the risk of jaw bone damage (o…
Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Triple therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new drug outperform standard care for head and neck cancer?
Disease control Not yet recruitingThis trial is testing whether an experimental drug called SYS6010 can better control advanced head and neck cancer compared to standard single-drug treatments. It involves about 340 adults aged 18-75 whose cancer has returned or spread and who have already tried platinum-based ch…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
Disease control Not yet recruitingThis trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can immunotherapy shrink Betel-Nut oral tumors before surgery?
Disease control Not yet recruitingThis trial tests whether giving two immunotherapy drugs—pembrolizumab and cetuximab—before surgery can shrink advanced oral cancers linked to betel-nut chewing. The study enrolls 20 people in the Northern Mariana Islands who have not yet received treatment. Researchers will measu…
Phase 2 • Sponsor: Peter Brett, MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a targeted drug combo outsmart advanced head and neck cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a speci…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
Disease control Not yet recruitingThis trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in peop…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Fish oil supplement aims to help head and neck cancer patients through tough treatment
Disease control Not yet recruitingThis pilot study will test whether a fish oil-enriched nutritional supplement, combined with weekly nutrition counseling, is feasible and safe for people with head and neck cancer undergoing chemoradiotherapy. Fifteen participants will start taking the supplement two weeks before…
Phase 1/2 • Sponsor: Anna Arthur, PhD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can improve outcomes for people with recurrent head and neck cancer. Participants will be randomly assigned to receive either the immunotherapy before and after surgery, or standard s…
Phase 2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can an immunotherapy combo shrink head and neck tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether adding the immunotherapy drug finotonlimab to chemotherapy before and after surgery can improve outcomes for people with stage II head and neck squamous cell carcinoma. Participants will receive either standard treatment (surgery plus chemoradiothera…
Phase 2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can an immunotherapy combo shrink throat tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial is testing whether giving the immunotherapy drug penpulimab together with chemotherapy before surgery can help people with locally advanced hypopharyngeal carcinoma, a type of head and neck cancer. The study will include about 15 adults aged 18 to 80 with resec…
Phase 2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a single eye injection shrink melanoma and save sight?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called RBP-01 (sotrastaurin), given as an injection into the eye, for people with primary uveal melanoma—a rare cancer of the eye. The study aims to see if the drug is safe and whether it can shrink the tumor enough to avo…
Phase 1/2 • Sponsor: ReBio Pharma • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Two-Drug combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…
Phase 2 • Sponsor: Dongguan People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Drug punch shrink eyelid tumors before surgery?
Disease control Not yet recruitingThis trial is testing whether giving two drugs—sintilimab and disitamab vedotin—before surgery can shrink tumors in people with a rare type of eyelid cancer called sebaceous gland carcinoma. Participants receive two cycles of the combination, then undergo surgery to remove the tu…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New cancer pill enters first human tests
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…
Phase 1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New scan could spare throat cancer patients from unnecessary radiation side effects
Disease control Not yet recruitingThis study tests whether a special scan (SPECT-CT) can show which side of the neck needs radiation in people with oropharyngeal cancer. Currently, both sides are treated to prevent hidden cancer spread, but this causes more side effects. The trial will enroll 128 patients to see …
Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Smart T-Cell engager aims to outsmart tumors in first human test
Disease control Not yet recruitingThis early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…
Phase 1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase 1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Oral drug elraglusib aims to tame advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…
Phase 1/2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New care model aims to close cancer treatment gaps for people with mental illness
Disease control Not yet recruitingThis trial tests a 24-week virtual care program called BRIDGE NET for people with serious mental illness who are starting cancer treatment. The program brings together oncology and mental health teams to plan care, provide early psychiatric support, and regularly check in with pa…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding ivonescimab—a drug that blocks both PD-1 and VEGF—to standard chemoradiotherapy improves outcomes for people with high-risk nasopharyngeal carcinoma. The study enrolls adults aged 18–65 with previously untreated stage T3N2M0 or stage III di…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to boost head and neck cancer treatment before and after surgery
Disease control Not yet recruitingThis study tests whether giving a combination of two drugs (becotatug vedotin and putlimab) before surgery, followed by radiotherapy and more putlimab after surgery, can improve outcomes for people with locally advanced head and neck cancer. The trial enrolls about 35 participant…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a painkiller blocker boost cancer immunotherapy?
Disease control Not yet recruitingThis early-phase trial tests whether adding axelopran—a drug that blocks opioid effects on the immune system—can help pembrolizumab (an immunotherapy) work better in people with advanced head and neck cancer who take opioids for pain. About 18 participants will receive both drugs…
Phase 1/2 • Sponsor: Glycyx Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Chemotherapy drug temozolomide under review for tough pituitary tumors
Disease control Not yet recruitingThis study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…
Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase 1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New PARP1 inhibitor targets Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …
Phase 1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
Disease control Not yet recruitingThis trial tests a follow-up strategy for people with nasopharyngeal cancer that has spread to neck lymph nodes (N3) after radiation therapy. Participants are assigned to standard follow-up or an enhanced approach that uses advanced imaging and a blood test (EBV DNA) to decide if…
Sponsor: Xuelei Ma MD • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New combo aims to tame HPV throat cancer with fewer side effects
Disease control Not yet recruitingThis early-phase trial tests whether a new drug (ATRN-119) combined with a single, precise dose of radiation to the neck can safely and effectively treat early-stage HPV-positive throat cancer before surgery. About 35 participants will take the drug daily for 10 days and receive …
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New proton therapy trial aims to reduce side effects in nasopharyngeal cancer
Disease control Not yet recruitingThis Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned…
Sponsor: Guangzhou Concord Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and an immune checkpoint inhibitor—in people with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after standard therapy. The goal is to see if the combination can shrink…
Phase 2 • Sponsor: Biying Chen • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New targeted pill holds promise for rare salivary gland cancer that spreads
Disease control Not yet recruitingThis phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Targeted drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control Not yet recruitingThis study tests a new drug, becotatug vedotin, combined with an immunotherapy (PD-1 inhibitor) in adults with advanced head and neck squamous cell carcinoma that cannot be surgically removed. The drug targets a protein called EGFR on cancer cells and delivers a toxin directly to…
Phase 2 • Sponsor: Feng Liu • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo targets HPV-Driven cancers in phase II trial
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—SYS6026 and Enlonstobart—in people with advanced solid tumors that have spread and are linked to HPV types 16 or 18. The study aims to see if the combination is safe and shows signs of shrinking tumors. Participants must be at …
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase 1/2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase 2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pastille could change head and neck cancer treatment
Disease control Not yet recruitingThis large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the canc…
Phase 3 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a Pre-Chemo drug shield bone marrow in head and neck cancer?
Disease control Not yet recruitingThis trial tests whether giving trilaciclib before chemotherapy and immunotherapy can protect bone marrow in people with advanced head and neck cancer. The goal is to reduce dangerous drops in blood cell counts, allowing patients to receive their full chemo doses on schedule. Abo…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy aims to shrink sinus tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests a new approach for people with advanced sinonasal cancer (a rare cancer of the nasal cavity and sinuses). Before surgery, patients receive standard chemotherapy (docetaxel and cisplatin) plus two immunotherapy drugs (sintilimab and ipilimumab). The goal i…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Early phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase 1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase 1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase 1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Glowing dye may save surgical flaps in head and neck cancer patients
Disease control Not yet recruitingThis trial tests whether a special dye called indocyanine green (ICG), injected during surgery, helps surgeons see blood flow in reconstructed tissue better than standard checks. About 244 adults having head and neck reconstruction will be randomly assigned to get the dye or stan…
Phase 4 • Sponsor: Region Skane • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase 2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for advanced HER2 cancers? drug trial launches
Disease control Not yet recruitingThis early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to stop aggressive nose cancer from coming back
Disease control Not yet recruitingThis phase 2 trial tests whether the drug becotatug vedotin can prevent cancer from returning in 140 patients with high-risk nasopharyngeal carcinoma who have completed standard chemo-radiation. Participants are randomly assigned to receive the drug or standard care. The main goa…
Phase 2 • Sponsor: Kai Hu • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
Disease control Not yet recruitingThis study tests a new treatment plan for people with HPV-positive oropharyngeal cancer (a type of throat cancer linked to HPV). The plan combines an immune-boosting drug (nogapendekin alfa inbakicept), a vaccine targeting HPV, chemotherapy, and a lower dose of radiation. The goa…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising new combo targets tough head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…
Phase 2 • Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase 1/2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase 1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Promising drug cocktail aims to shrink aggressive nasal tumors before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of anlotinib (a targeted therapy) and epirubicin (chemotherapy) before surgery can improve outcomes for people with advanced sinonasal adenoid cystic carcinoma, a rare and aggressive cancer of the nasal cavity and sinuses. About 76 pa…
Phase 2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …
Early phase 1 • Sponsor: Peking University Shenzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase 1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection targets cancer fluid in lungs and belly
Disease control Not yet recruitingThis early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…
Phase 1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase 1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
No-Stitch eye glue could spare patients pain and scarring
Disease control Not yet recruitingThis study tests a special hydrogel that acts like a glue to hold eye tissues together during surgery, avoiding the need for stitches. Stitches can cause pain, swelling, and scarring, but this gel uses light to bond quickly and gently. The trial will include 20 people with cornea…
Sponsor: Suxia Li • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New antibody injection takes aim at Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis study tests a new drug called TQB2922, given as a shot under the skin, for people with head and neck cancer that has come back or spread. The drug is a special antibody that targets two proteins (EGFR and c-Met) involved in cancer growth. The trial has two parts: first, find…
Phase 1/2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase 1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug IN10028 tested for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…
Phase 1 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug 'Unmasks' cancer cells to immune system in early trial
Disease control Not yet recruitingThis early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo before surgery shows promise
Disease control Not yet recruitingThis study tests whether giving two drugs (becotatug vedotin and pucotenlimab) before surgery can shrink tumors in people with recurrent head and neck cancer that has stopped responding to standard treatments. About 42 adults with EGFR-positive cancer will receive 3 cycles of the…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo targets hard-to-treat lymphoma
Disease control Not yet recruitingThis study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SYS6051 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.
Phase 1 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA shot targets Hard-to-Treat cancers in early human test
Disease control Not yet recruitingThis early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy takes aim at Hard-to-Treat salivary gland cancer
Disease control Not yet recruitingThis phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease …
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Radiation-Free hope: study tests if surgery alone is enough for rare nasal cancer
Disease control Not yet recruitingThis study looks at whether patients with a rare nasal cancer (sinonasal adenoid cystic carcinoma) can safely avoid radiation after surgery if the tumor was completely removed. About 200 patients will choose either surgery alone or surgery plus radiation, and researchers will tra…
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat nasopharyngeal cancer: ivonescimab trial launches
Disease control Not yet recruitingThis phase 2 trial is testing a drug called ivonescimab in 42 people with a type of head and neck cancer (nasopharyngeal carcinoma) that has stopped responding to standard immunotherapy and chemotherapy. The drug is given every 3 weeks by IV. Researchers will measure how many pat…
Phase 2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktail aims to stop head and neck cancer return
Disease control Not yet recruitingThis study tests whether adding the drug benmelstobart to standard radiotherapy and nimotuzumab can help prevent head and neck cancer from coming back after surgery. About 386 patients with intermediate-risk features will be randomly assigned to one of two groups. The main goal i…
Phase 2/3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug FXB0871 takes on advanced cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail takes on bulky head and neck tumors
Disease control Not yet recruitingThis phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to a special type of radiation and standard chemotherapy can help people with advanced, bulky head and neck cancer live longer without the disease getting worse. The study will enroll 2…
Phase 2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether giving radiation along with immunotherapy before surgery works better than immunotherapy alone for people with advanced head and neck cancer. About 36 adults with treatable but advanced cancer will be split into two groups. The goal is to see if the combi…
Phase 2 • Sponsor: Chen Chunyan • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising new combo aims to shrink returning throat tumors
Disease control Not yet recruitingThis study tests a new treatment for people whose nasopharyngeal cancer has come back and cannot be surgically removed. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy, followed by radiation and continued immunotherapy. The goal i…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo aims to stop advanced nose cancer from coming back
Disease control Not yet recruitingThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemotherapy and radiation can help prevent cancer from returning in people with high-risk, advanced nasopharyngeal carcinoma. About 442 adults aged 18-65 …
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo aims to shrink oral cancers before surgery
Disease control Not yet recruitingThis study tests whether giving two drugs together before surgery can shrink advanced mouth or throat cancers. The drugs are becotatug vedotin and pucotenlimab. About 26 people with stage III or IVa cancer will take part. The goal is to see if the cancer nearly or completely disa…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo aims to shrink throat tumors before surgery
Disease control Not yet recruitingThis study tests whether giving two drugs (vibecortamab and putilimab) before surgery can help shrink tumors in people with locally advanced laryngeal cancer. About 10 adults aged 18-80 with resectable cancer will receive the combination, then have surgery. The main goal is to se…
Phase 1/2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New chemo cocktail aims to tame advanced head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests whether a combination of two chemotherapy drugs, cyclophosphamide and etoposide, can control advanced head and neck cancer in adults who have already tried standard treatment. 120 participants will receive either the drug combo or methotrexate for 6 month…
Phase 2 • Sponsor: National Cancer Institute, Egypt • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Snake venom protein tested as cancer treatment in humans
Disease control Not yet recruitingThis early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…
Phase 1 • Sponsor: Celtic Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for hard-to-treat head and neck cancer: drug combo enters phase 2 trial
Disease control Not yet recruitingThis study tests whether adding ficerafusp alfa to the immunotherapy nivolumab can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that has stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will take part. The goal is …
Phase 2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase 1/2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail aims to beat back aggressive throat cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can improve outcomes for people with high-risk nasopharyngeal cancer. About 514 participants will be randomly assigned to receive either the new combo or stan…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase 1/2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New scope technique targets tough sinus tumors
Disease control Not yet recruitingThis study will test whether a special endoscopic (scope-based) surgery can completely remove tumors in difficult areas of the nose and sinuses. About 25 adults with these tumors will take part. Researchers will measure how often the tumor is fully removed, how much blood is lost…
Sponsor: Assiut University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy before surgery shows promise for oral cancer
Disease control Not yet recruitingThis study tests whether giving the immunotherapy drug nivolumab before surgery can shrink tumors in people with advanced oral cancer. About 60 adults with resectable oral squamous cell carcinoma will receive nivolumab, then have surgery. Researchers will also look for biomarkers…
Phase 2 • Sponsor: Prof. Lars Olaf Cardell • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New shorter radiation regimen aims to cut treatment time for head and neck cancer patients
Disease control Not yet recruitingThis phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while pos…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …
Phase 1/2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Immune booster: donor NK cells aim to cut cancer recurrence
Disease control Not yet recruitingThis trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can reduce the risk of cancer returning in people with advanced nasopharyngeal cancer. The study has two phases: first, finding the safest dose of NK cells, then testing th…
Phase 1/2 • Sponsor: Singapore General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Iron nanoparticles could supercharge radiation against cancer
Disease control Not yet recruitingThis Phase 2 trial tests an experimental iron nanoparticle injection (CNSI-Fe) given directly into tumors along with standard radiotherapy. The goal is to see if the combination shrinks tumors better than radiation alone. The study will enroll 52 adults with head and neck cancer …
Phase 2 • Sponsor: Sichuan Enray Pharmaceutical Sciences Company • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Video game tech could make oral cancer surgery more precise
Disease control Not yet recruitingThis study tests whether a mixed reality system, similar to video game technology, can help surgeons remove oral cancer and rebuild the area more accurately. Thirty people with oral cancer will be split into three groups: one using mixed reality, one using a virtual surgical guid…
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New cancer drug SIG001 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…
Phase 1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New triple therapy offers hope for hard-to-treat nose and throat cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in 52 adults with recurrent or metastatic nasopharyngeal carcinoma that has failed at least one prior treatment. The goal is to find the safest dose and see how many patients' tumors shrink. Par…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New light treatment could fight oral cancer without surgery
Disease control Not yet recruitingThis study tests a low-cost approach to treat pre-cancerous and cancerous mouth lesions using a drug (5-ALA) that makes abnormal cells sensitive to light, followed by laser light delivered through a handheld device. The goal is to destroy these lesions without surgery. The trial …
Phase 2 • Sponsor: University of Massachusetts, Boston • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New study tests best Follow-Up after surgery for oral cancer
Disease control Not yet recruitingThis study looks at people with advanced mouth or throat cancer who had chemotherapy and immunotherapy before surgery. After surgery, they will either get radiation, immunotherapy maintenance, or just be watched. The goal is to see which approach helps them live longer without th…
Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug QLS5308 enters human testing for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…
Phase 1/2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo therapy aims to boost survival in head and neck cancer patients
Disease control Not yet recruitingThis study tests whether adding the immunotherapy drug camrelizumab to either an EGFR antibody or chemotherapy helps people with advanced head and neck cancer live longer. About 246 adults with stage III or IV head and neck cancer will receive the treatment before and after surge…
Phase 3 • Sponsor: Yue He, MD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to personalize throat cancer treatment
Disease control Not yet recruitingThis study tests a new approach for people with a certain type of throat cancer that is not low-risk. Participants first receive a combination of chemotherapy, immunotherapy, and a special type of radiation called lattice radiotherapy. Then, based on how much the tumor shrinks, t…
Phase 1/2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug T320 targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase 1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered macrophages take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Triple threat: radiation, chemo, and immunotherapy before surgery shows promise for oral cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether giving a short course of targeted radiation (SBRT) followed by chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced oral or HPV-negative throat cancer. About 184 participants will be randomly assigned to rece…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail aims to fight Hard-to-Treat throat cancer
Disease control Not yet recruitingThis Phase 2 trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy) and Pucotenlimab (an immunotherapy)—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study will enroll 30 adults and measure how long the cancer stay…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests whether giving a combination of the immunotherapy drug camrelizumab and two chemotherapy drugs (paclitaxel and carboplatin) before surgery can improve outcomes for people with advanced oral cavity or larynx cancer. Fifty participants will receive three cy…
Phase 2 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Timing is everything: new trial seeks to boost cancer treatment by scheduling immunotherapy just right
Disease control Not yet recruitingThis Phase II trial tests whether giving the immunotherapy drug toripalimab on different days during chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 198 participants will receive standard chemotherapy plus toripalimab on Day 1, Day 5, or Da…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New triple therapy aims to wipe out head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery can shrink or eliminate tumors in people with advanced head and neck cancer. About 30 adults aged 18-70 with stage III/IVA disease who have not had prior tr…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo aims to shrink Hard-to-Treat throat cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs—scipibaimab and tislelizumab—can shrink tumors in people with recurrent or metastatic nasopharyngeal carcinoma that has worsened after first-line treatment. About 37 adults whose cancer has not responded to platinum chemotherap…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cocktail of drugs aims to stop High-Risk throat cancer in its tracks
Disease control Not yet recruitingThis Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or st…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New immunotherapy combo aims to stop head and neck cancer return
Disease control Not yet recruitingThis phase II trial tests the immunotherapy drug sintilimab combined with radiotherapy in patients with resectable locally advanced head and neck cancer. Participants receive sintilimab before surgery, then again after surgery along with radiation. The study aims to see if this a…
Phase 2 • Sponsor: chen chao Professor • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could less immunotherapy be just as good for advanced nose cancer?
Disease control Not yet recruitingThis phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive eit…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New radiation combo aims to shrink oral tumors before surgery
Disease control Not yet recruitingThis early-phase study tests a new type of radiation (lattice radiotherapy) given with chemotherapy and immunotherapy before surgery for oral cavity cancer. About 30 adults with advanced but removable tumors will receive different radiation doses to find the safest level. The goa…
Phase 1 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy cocktail aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study tests whether adding chemotherapy to the immunotherapy drug toripalimab before surgery helps keep head and neck cancer from coming back. About 154 adults with advanced but operable cancer will get either toripalimab alone or with chemo for two cycles, then have surgery…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can cheap eye drops stop Kids' nearsightedness after cataract surgery?
Disease control Not yet recruitingThis study tests whether low-dose atropine eye drops (0.05%) can slow down worsening nearsightedness in children aged 1 to 7 who have had cataract surgery with an artificial lens implant. Fifty children will receive the drops for 12 months, and researchers will measure changes in…
Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail offers hope for Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) in 30 adults with recurrent or metastatic head and neck cancer that has not responded to previous treatments. The goal is to see if this therapy can shrink tumors and improve survival. Partic…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Booster shot may extend time between surgeries for RRP patients
Disease control Not yet recruitingThis study tests whether a one-time booster dose of the Gardasil-9 vaccine can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths keep coming back in the airway. Researchers will enroll 50 adults…
Phase 1/2 • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Microtransplantation: a new hope for advanced cancer patients?
Disease control Not yet recruitingThis early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …
Phase 1 • Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New mRNA vaccine trial targets Virus-Linked cancers
Disease control Not yet recruitingThis early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…
Early phase 1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control Not yet recruitingThis study tests whether adding fianlimab to the standard cemiplimab plus chemotherapy can better shrink tumors in adults with advanced HPV-positive head and neck cancer. About 90 participants will receive either the two-drug or three-drug combination before radiation. The goal i…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Supercharged T-Cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …
Early phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Nerve cut may supercharge tongue cancer treatment
Disease control Not yet recruitingThis phase II trial tests whether surgically cutting the lingual nerve (which controls tongue sensation) can make chemoimmunotherapy work better for people with advanced tongue cancer. 69 adults with stage T3/T4 tongue cancer will receive the nerve cut along with two cycles of ti…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug HX111 enters early human trials
Disease control Not yet recruitingThis study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase 1/2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to fix Chemo-Caused low platelets
Disease control Not yet recruitingThis Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy aims to control returning throat cancer
Disease control Not yet recruitingThis study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunothera…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could immunotherapy let surgeons do less without hurting survival?
Disease control Not yet recruitingThis study tests whether people with advanced head and neck cancer who respond to immunotherapy can safely have a smaller, less invasive surgery than usual. The goal is to preserve organ function and quality of life without lowering the chance of survival. About 356 participants …
Phase 3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising cocktail aims to save voice boxes in head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two targeted drugs (sintilimab and nimotuzumab) plus chemotherapy for people with advanced head and neck cancer that hasn't spread. The goal is to see if this approach can shrink tumors enough to avoid removing the larynx (voice box). The…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for rare cancers: china launches massive drug trial
Disease control Not yet recruitingThis study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…
Phase 1/2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase 1/2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New gene therapy trial hopes to tame advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Eye surgery showdown: which technique best prevents pterygium return?
Disease control Not yet recruitingThis study compares two surgical techniques for preventing regrowth of a pterygium, a non-cancerous eye growth. After removing the growth, surgeons will cover the area with either a rotated flap of nearby tissue or a free graft from under the eyelid. 342 patients will be randomly…
Sponsor: College of Physicians and Surgeons Pakistan • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could skipping some neck radiation be just as effective?
Disease control Not yet recruitingThis study tests whether it is safe to skip radiation to a specific neck area (Level Va) in patients with a type of throat cancer called nasopharyngeal carcinoma. About 474 newly diagnosed patients without cancer spread will be randomly assigned to standard radiation or a reduced…
Phase 3 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug duo aims to shrink throat tumors before standard care
Disease control Not yet recruitingThis study tests whether giving two drugs (pembrolizumab and MRG-003) before standard chemoradiation can shrink tumors in people with advanced nasopharyngeal cancer linked to Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive 3 cycles of the drug combo, t…
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Mushroom-Derived compound joins forces with radiation and immunotherapy to fight advanced cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…
Phase 2 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase 1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a simple pill before surgery beat back head and neck cancer?
Disease control Not yet recruitingThis study tests whether taking a short course of capecitabine pills before surgery can shrink tumors and improve outcomes for people with HPV-negative head and neck cancer. About 75 adults with stage III or IVa cancer will be randomly assigned to either standard care or capecita…
Phase 2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug aims to stop chemo side effect in nose and throat cancer
Disease control Not yet recruitingThis study tests whether the drug hetrombopag can prevent severe low platelet counts caused by chemotherapy in people with nasopharyngeal carcinoma. About 35 patients who already had low platelets during a previous chemo cycle will take hetrombopag tablets daily during their next…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for tough cancers: experimental drug TB511 enters human trials
Disease control Not yet recruitingThis early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…
Phase 1/2 • Sponsor: Twinpig Biolab, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New mRNA vaccine takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…
Phase 1/2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New combo therapy targets stubborn nasopharyngeal cancer in phase 3 trial
Disease control Not yet recruitingThis study tests whether adding chemotherapy to immunotherapy works better than immunotherapy alone for people with advanced nasopharyngeal cancer whose cancer did not fully respond to initial treatment. About 516 adults aged 18-65 with stage II-III disease will receive either th…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New radiation dose may tame eye cancer with fewer side effects
Disease control Not yet recruitingThis study tests a lower dose of radiation (12 Gy in 6 sessions) for people with low-grade B-cell orbital lymphoma, a slow-growing eye cancer. The goal is to see if this dose can control the tumor as well as the standard higher dose (24-25 Gy) while causing fewer long-term side e…
Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New gene therapy trial hopes to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …
Phase 1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase 1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom immune attack: new gene therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug aims to fix Chemo-Induced low platelets
Disease control Not yet recruitingThis study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…
Sponsor: Jun wang • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…
Phase 1/2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:39 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New hope for cancer patients: drug may fix Radiation-Related low platelets
Disease control Not yet recruitingThis phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…
Phase 2 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:03 UTC
-
New combo aims to wipe out returning nose cancer with chemo, immunotherapy, and surgery
Disease control Not yet recruitingThis phase II trial tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before surgery, followed by maintenance pembrolizumab, can improve outcomes for people with locally recurrent nasopharyngeal carcinoma. About 53 participants will receive up to 6 cycles of…
Phase 2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 26, 2026 13:57 UTC
-
New Virus-Immunotherapy combo tackles Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new approach for people with recurrent or metastatic head/neck cancer or esophageal cancer. The treatment combines a virus that delivers endostatin directly into tumors with an immunotherapy drug (PD-1 inhibitor). The goal is to see if the comb…
Phase 1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 26, 2026 13:51 UTC
-
New PET tracer aims to light up hidden cancer targets
Diagnosis Not yet recruitingResearchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…
Early phase 1 • Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Can a glowing dye show surgeons where head and neck tumors end?
Diagnosis Not yet recruitingResearchers at Washington University School of Medicine are studying whether a fluorescent dye called indocyanine green can help visualize the edges of head and neck squamous cell carcinoma during surgery. The study plans to enroll 25 adults who are having surgery for confirmed o…
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
AI reads tumor slides to match cancer patients with trials
Diagnosis Not yet recruitingMany cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
MRI scans may reveal which throat cancer patients need stronger treatment
Diagnosis Not yet recruitingThis study tests whether special MRI scans can predict how well HPV-positive throat cancer responds to standard chemotherapy and radiation. Researchers will scan 30 adults before treatment and track their outcomes. The goal is to see if MRI patterns can identify low-risk patients…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Can a new tracer reveal hidden tumors?
Diagnosis Not yet recruitingThis trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …
Early phase 1 • Sponsor: Lumina Pharmaceuticals Inc • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
New radioactive antibody could light up Hard-to-Treat cancers
Diagnosis Not yet recruitingThis early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…
Phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Glowing cancer cells: a new way to see tumors during surgery?
Diagnosis Not yet recruitingThis trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
A simple breath test might spot multiple cancers before symptoms appear
Diagnosis Not yet recruitingThis trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a new imaging tracer outperform standard scans in finding hidden tumors?
Diagnosis Not yet recruitingThis trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
Can a 1-Millimeter PET camera reveal hidden tumor details?
Diagnosis Not yet recruitingThis pilot study is testing a new PET camera with 1-millimeter resolution to see if it can produce clearer images of head and neck cancers compared to standard PET scanners. Ten people scheduled for surgery will receive an extra scan with the high-resolution camera. The goal is t…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
A simple eye-tracking test may replace button-pressing exams for pituitary tumor patients
Diagnosis Not yet recruitingThis study tests whether a new eye-tracking device called SONDA can accurately measure visual field loss in people with pituitary tumors. Standard visual field tests require patients to press a button when they see lights, which can be tiring and unreliable. The SONDA test instea…
Sponsor: University Medical Center Groningen • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
AI reads MRI scans to reveal hidden brain tumor types in children before surgery
Diagnosis Not yet recruitingThis study is developing an artificial intelligence (AI) system that can analyze standard MRI brain scans to determine the specific molecular subtype of a child's brain tumor before surgery. The research includes 1,400 children under 18 with suspected brain tumors, using both pas…
Sponsor: Huashan Hospital • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New imaging agent could sharpen cancer treatment decisions
Diagnosis Not yet recruitingThis early-phase study will test a new radioactive tracer called [18F]-AraG in just 5 people with advanced head and neck cancer. Participants will receive two PET/CT scans (before and during standard chemoradiotherapy) to see if the tracer's uptake matches immune cell activity an…
Early phase 1 • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
New scan could sharpen detection of head and neck cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New radioactive tracers could spot cancers more clearly
Diagnosis Not yet recruitingThis early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…
Early phase 1 • Sponsor: Hua Pang • Aim: Diagnosis
Last updated Jun 27, 2026 13:08 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Blood test could spot hidden throat cancers before symptoms start
Diagnosis Not yet recruitingThis study aims to see if a simple blood test can find HPV-related oropharyngeal cancer early in men aged 50 and older who have no symptoms. Researchers will check blood for two markers of HPV and then follow up with those who test positive to find and treat any tumors. If succes…
Sponsor: UNICANCER • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
AI-Powered endoscopy aims to spot head and neck cancer earlier
Diagnosis Not yet recruitingThis study will test artificial intelligence algorithms that analyze video from routine endoscopies of the head and neck. The AI will try to detect, classify (benign vs. malignant), and outline lesions, comparing its performance to doctors and lab results. About 283 adults with s…
Sponsor: Istituto Italiano di Tecnologia • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New 'Smart' PET scan could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Glow-in-the-dark dye could help surgeons spot cancer during head and neck surgery
Diagnosis Not yet recruitingThis early-phase trial tests a fluorescent dye called ABY-029 that may help surgeons see head and neck cancer during surgery. About 24 adults with head and neck squamous cell carcinoma will receive a tiny amount of the dye before surgery. Researchers will check safety and find th…
Phase 1 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New scan could spot invisible brain tumors
Diagnosis Not yet recruitingThis study tests whether a special PET scan (18FET) can find small pituitary tumors that standard MRI scans miss. About 30 adults with suspected hormone-secreting pituitary tumors will receive the scan. If it works, it could help doctors decide on surgery or radiation without nee…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
AI could spot mouth cancer early from a simple photo
Diagnosis Not yet recruitingThis study will collect thousands of photos of mouth lesions from patients seen over 50 years at a French hospital. Experts will review each photo to confirm the diagnosis. Researchers will then use these images and patient data to train an AI system to automatically identify can…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:07 UTC
-
Could a simple scan replace biopsies for cancer immunotherapy?
Diagnosis Not yet recruitingThis study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
New blood test aims to predict which cancer patients will benefit from immunotherapy
Diagnosis Not yet recruitingThis study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…
Sponsor: OncoHost Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 07:59 UTC
-
Faster, cheaper scans could revolutionize cancer radiation planning
Diagnosis Not yet recruitingThis study will test whether a special CT scan (dual-energy CT) can be as good as MRI for mapping tumors and healthy organs before radiation therapy. Researchers will enroll 80 people with brain, bone, head/neck, or lung cancer. If DECT works well, it could save time and money co…
Sponsor: Aalborg University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
A steroid premedication may tame the immune reaction to a melanoma therapy
Prevention Not yet recruitingThis phase 2 trial tests whether a low dose of the steroid dexamethasone, given before the first four infusions of tebentafusp, can prevent cytokine release syndrome in people with advanced uveal melanoma. Tebentafusp is a standard first-line treatment for this eye cancer, but it…
Phase 2 • Sponsor: University of California, San Diego • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Psilocybin trial aims to shield cancer patients from chemo nerve pain
Prevention Not yet recruitingThis Phase 2 trial tests whether psilocybin, a psychedelic compound, can prevent or lessen chemotherapy-induced peripheral neuropathy (nerve damage) in people with breast, colorectal, or head and neck cancer. About 83 participants will receive either psilocybin, a low-dose placeb…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
New trial aims to slash deadly bloodstream infections from hospital tubes
Prevention Not yet recruitingThis study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…
Sponsor: The University of Queensland • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
New Gel-Like wrap could stop chronic pain after cancer reconstruction
Prevention Not yet recruitingThis pilot study tests whether placing a soft tissue matrix over a nerve during forearm flap surgery can prevent chronic pain and numbness. Eighty head and neck cancer patients will be randomly assigned to receive either the matrix or standard closure. The main goal is to see if …
Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Light therapy may shield kids with cancer from chemo mouth sores
Prevention Not yet recruitingThis study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…
Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Can light be the new shield against radiation mouth sores?
Prevention Not yet recruitingThis pilot study tests two light therapy devices—one placed inside the mouth and one outside—to prevent and treat painful mouth sores caused by radiation therapy. Sixty adults with oral cavity or oropharynx cancer will receive light sessions twice a week for prevention, then thre…
Sponsor: Centre Paul Strauss • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Simple scope procedure may prevent radiation damage in recurrent nose cancer
Prevention Not yet recruitingThis study tests whether removing a thin layer of tissue (pseudomembrane) from the back of the nose using a scope can prevent radiation-induced tissue death in patients with recurrent nasopharyngeal cancer who have had repeat radiation. About 40 adults in China will undergo the p…
Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:24 UTC
-
Herbal mouthwash may stop radiation mouth sores before they start
Prevention Not yet recruitingThis study tests whether a modified herbal mouthwash can prevent painful mouth sores caused by radiation therapy in people with head and neck cancer. About 156 participants will use either the herbal mouthwash or a placebo during their radiation treatment. The goal is to see if t…
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Light therapy may soothe chemo mouth sores in children
Prevention Not yet recruitingThis study tests if a special light (photobiomodulation) can prevent and treat painful mouth sores caused by chemotherapy in children aged 4-17 with cancer. Half of the 49 participants will get light therapy, and the other half will get a standard gel. The goal is to see if the l…
Sponsor: Universidad de Guanajuato • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Can a stem cell spray stop radiation mouth pain?
Prevention Not yet recruitingThis study tests an oral spray made from stem cell exosomes to prevent severe mouth sores in head and neck cancer patients undergoing radiation. 200 participants will use the spray three times daily, starting a week before radiation and continuing for two weeks after. The goal is…
Phase 2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
Glutamine supplement may shield kids from chemo nerve pain
Prevention Not yet recruitingThis study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…
Phase 3 • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Simple nasal spray may prevent hearing loss in cancer survivors
Prevention Not yet recruitingThis study tests whether a steroid nasal spray can prevent fluid buildup in the middle ear, a common side effect of radiation therapy for nasopharyngeal cancer. About 168 adults who are about to start radiation will use either the spray or a placebo for 12 months. The goal is to …
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Prevention
Last updated Jun 27, 2026 07:52 UTC
-
Can steroids, a migraine drug, or tongue exercises save nerves after throat cancer treatment?
Symptom relief Not yet recruitingPeople treated with radiation for oropharyngeal cancer can later develop damage to cranial nerves, especially the nerve that controls the tongue. This trial tests four approaches to see if they are safe and practical: high-dose prednisone, the injectable drug fremanezumab, a home…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 21, 2026 15:00 UTC
-
Live music meets virtual reality: can a Three-Session program reach advanced cancer patients in palliative care?
Symptom relief Not yet recruitingResearchers at Hospital Universitario Austral in Argentina are testing whether a structured three-session music therapy program called MUSPAL360 can be delivered to hospitalized adults with advanced cancer receiving palliative care. The program combines live music therapy with 36…
Sponsor: Austral University, Argentina • Aim: Symptom relief
Last updated Sep 21, 2026 15:00 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could early palliative care reduce aggressive End-of-Life cancer treatments?
Symptom relief Not yet recruitingThis study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly…
Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can orange peel gel soothe radiation mouth sores?
Symptom relief Not yet recruitingResearchers are testing a gel made from orange peel extract to see if it can reduce the severity of mouth sores caused by radiation therapy in people with head and neck cancer. Thirty adults receiving radiation will be split into two groups: one gets the orange peel gel, the othe…
Sponsor: Alexandria University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Shorter radiation course tested for advanced head and neck cancer
Symptom relief Not yet recruitingResearchers compare two palliative radiation schedules for people with incurable head and neck cancer. The standard Split Course takes several weeks and often causes hard-to-tolerate side effects. The study tests whether a shorter Quad Shot regimen can shrink tumors and ease symp…
Sponsor: Instituto Nacional de Cancerologia, Columbia • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a smart breathing device make life with a tracheostomy more comfortable?
Symptom relief Not yet recruitingThis trial tests whether the TrachPhone, a device that adds heat and moisture to the air you breathe, can improve comfort and lung recovery in people who have a tracheostomy after head and neck cancer surgery. Half of the 80 participants will use the TrachPhone, while the other h…
Phase 1/2 • Sponsor: University of South Florida • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could daily swallowing exercises ease a harsh side effect of cancer treatment?
Symptom relief Not yet recruitingThis trial tests whether a structured swallowing rehabilitation program can improve swallowing function, reduce jaw stiffness, and ease pain in people with head and neck cancer. Researchers will randomly assign 80 patients who have had radiation or chemoradiotherapy to either the…
Sponsor: Delta University for Science and Technology • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
A Multi-Pronged attack on Post-Surgery nausea: a new trial for head and neck cancer patients
Symptom relief Not yet recruitingThis trial tests whether a combination of antiemetic strategies can better prevent postoperative nausea and vomiting (PONV) in patients undergoing flap surgery for head and neck cancer. Participants will be randomly assigned to receive either a standard antiemetic protocol or a m…
Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
Can planned IV fluids tame the brutal side effects of head and neck cancer treatment?
Symptom relief Not yet recruitingThis trial tests whether giving IV fluids on a fixed schedule during chemoradiation for head and neck cancer can reduce severe side effects like mouth sores, swallowing problems, and kidney injury. Half of the participants will receive IV fluids twice a week starting in week 3 of…
Sponsor: West Virginia University • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Can a High-Tech camera replace the dreaded mask in cancer radiation?
Symptom relief Not yet recruitingThis pilot study explores whether surface-guided radiotherapy (SGRT) can help head and neck cancer patients who feel anxious or claustrophobic during standard radiation treatment. Instead of a tight thermoplastic mask, SGRT uses a camera system to track patient position in real t…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Could a ketamine mouthwash ease radiation mouth pain?
Symptom relief Not yet recruitingThis study tests if a ketamine oral rinse can relieve pain from mouth sores (mucositis) caused by radiation therapy in head and neck cancer patients. About 62 adults receiving radiation will use the rinse and report their pain levels. The goal is to see if this simple rinse impro…
Phase 2 • Sponsor: University of Oklahoma • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Symptom relief Not yet recruitingThis study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a simple cough exercise restore strength after head and neck cancer?
Symptom relief Not yet recruitingThis study tests whether a cough skill training program can help people with head and neck cancer cough more effectively. Participants practice voluntary coughs using a handheld device during sessions and at home. The goal is to see if the training is feasible and if it improves …
Sponsor: Boston University Charles River Campus • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Brain games may rev up thinking and driving after cancer treatment
Symptom relief Not yet recruitingThis study tests whether a 10-week home-based video game training program can improve cognitive function and driving performance in head and neck cancer survivors who report thinking difficulties after radiation or chemoradiation. Participants will complete questionnaires, use a …
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Texting your symptoms: a digital coach for cancer side effects?
Symptom relief Not yet recruitingThis trial tests whether a digital platform that sends symptom check-ins and self-care tips via text message can help people with head and neck or lung cancer report their health more consistently. Participants either receive standard symptom questionnaires or get extra monitorin…
Sponsor: Henry Ford Health System • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Smartphone program aims to boost hope and recovery in oral cancer survivors
Symptom relief Not yet recruitingThis study tests whether a mobile-based rehabilitation program, built on the PERMA-H model of well-being, can improve hope, self-confidence, and social support in people recovering from a tracheostomy due to oral cancer. Participants use a WeChat mini-program with a chatbot and t…
Sponsor: Hainan Medical College • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
AI coach helps oral cancer patients move again
Symptom relief Not yet recruitingThis study tests whether an AI-powered physiotherapy system can help oral cancer patients improve mouth, neck, and shoulder movement after surgery or radiation. Fifteen participants will use the system for 4 to 6 weeks, doing daily exercises prescribed by the AI. The goal is to s…
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Could a simple spray shield cancer patients from radiation burns?
Symptom relief Not yet recruitingThis trial tests whether a spray containing superoxide dismutase, an antioxidant enzyme, can reduce severe skin reactions caused by radiation therapy. Head and neck cancer patients scheduled for radiotherapy apply the spray five times daily to the treated skin area. The study com…
Phase 2 • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Can a buddy system help head and neck cancer patients? new study aims to find out
Symptom relief Not yet recruitingThis trial tests whether a one-on-one peer support program is feasible for people with head and neck cancer. Patients (mentees) are matched with cancer survivors (mentors) for emotional and informational support. The study will enroll 56 participants and measure how many actually…
Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
New surgical wrap aims to cut palate injuries in half
Symptom relief Not yet recruitingThis study compares two ways to lift the soft palate during throat surgery to see which causes fewer injuries. About 138 people aged 2 to 70 who need this type of surgery will be randomly assigned to either the standard double-strap method or a new full-wrap method. The goal is t…
Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Ancient herbal formula may soothe radiation burns in the mouth
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese herbal drink called Sancai Fengsui Decoction can help heal painful mouth sores caused by radiation therapy for head and neck cancer. About 126 adults who have developed moderate to severe mouth sores after radiation will receive eith…
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Acupuncture with electric current may help stroke survivors speak again
Symptom relief Not yet recruitingThis study tests whether adding electroacupuncture at specific acupoints (Xuanzhong and Tongli) to standard speech therapy improves language recovery in people with post-stroke aphasia. Participants receive daily electroacupuncture sessions for four weeks, plus speech therapy. Th…
Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
Symptom relief Not yet recruitingThis trial compares early versus delayed acupuncture to reduce dry mouth caused by chemoradiation in head and neck cancer patients. Participants receive acupuncture either during chemoradiation or after, and their dry mouth symptoms are tracked for a year. The goal is to find the…
Sponsor: National University Hospital, Singapore • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New study: can early palliative care help head and neck cancer patients suffer less?
Symptom relief Not yet recruitingThis study tests whether adding palliative care early — alongside standard chemoradiotherapy — can improve symptoms and quality of life for people with advanced head and neck cancer that cannot be surgically removed. Researchers will compare two groups: one receiving standard tre…
Sponsor: Portuguese Oncology Institute, Coimbra • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Ice chips vs. mouth sores: simple trick may ease chemo side effect
Symptom relief Not yet recruitingThis study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New rehab program aims to ease hidden side effects of head and neck cancer treatment
Symptom relief Not yet recruitingThis study tests a coordinated rehab program for 74 veterans with head and neck cancer. The program combines standard swallowing therapy with proactive hearing and balance checks and a nurse assessment to find other rehab needs. The goal is to reduce stress and improve well-being…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Simple exercises may soothe chemo nerve damage
Symptom relief Not yet recruitingThis study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Taurine: a simple supplement to fight radiation mouth sores?
Symptom relief Not yet recruitingThis phase 2 trial tests whether taking taurine (a common amino acid) can prevent or reduce severe mouth sores caused by radiation therapy in people with nasopharyngeal cancer. 130 patients will take taurine pills or receive standard care starting 3 days before radiation until 1 …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Nose ointment may ease Radiation's brutal mouth pain
Symptom relief Not yet recruitingThis study tests whether a common antibiotic ointment applied inside the nose can reduce severe mouth and throat pain caused by radiation therapy in head and neck cancer patients. About 126 participants will receive either the antibiotic or a placebo, and neither they nor their d…
Phase 2 • Sponsor: David Palma • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Miracle fruit may bring back taste for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Could a simple salt water soak ease radiation skin pain?
Symptom relief Not yet recruitingThis study tests whether daily soaks with normal saline (salt water) can reduce severe skin reactions caused by radiation therapy. About 150 adults with head and neck cancer or sarcoma will either get standard care or standard care plus a 5-10 minute saline soak each day. Researc…
Sponsor: King Hussein Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New program aims to ease cancer survivors' fear of recurrence
Symptom relief Not yet recruitingThis study develops and tests a support program for cancer survivors who worry about their cancer returning. 150 adults who finished treatment for breast, head and neck, colon-rectal, or prostate cancer will join. Depending on their level of fear, they will receive education, psy…
Sponsor: National Taipei University of Nursing and Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Protein shake may shield cancer patients from painful mouth sores
Symptom relief Not yet recruitingThis study tests if a daily protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo drink without protein during their radiation treatment. The g…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New beam angle may spare cancer patients from dry mouth and swallowing woes
Symptom relief Not yet recruitingThis study tests whether a new way of aiming radiation beams (non-coplanar) can reduce side effects like dry mouth and swallowing problems in people with head and neck cancer. About 70 adults with cancer of the mouth or throat will be randomly assigned to standard or new radiatio…
Sponsor: Centre Georges Francois Leclerc • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Herbal soak may soothe Chemo's painful side effects
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…
Sponsor: Peking University Third Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can a simple cream prevent radiation burns? new trial aims to find out.
Symptom relief Not yet recruitingThis study compares two skin-protective strategies—a fragrance-free emollient plus foam dressing versus a silicone-based barrier film—in 104 head and neck cancer patients receiving TomoTherapy. The goal is to see which approach better prevents or reduces painful radiation dermati…
Sponsor: King Faisal Specialist Hospital & Research Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could hydrogen water soothe mouth pain after oral cancer surgery?
Symptom relief Not yet recruitingThis study tests whether rinsing with hydrogen water can reduce mouth inflammation and pain in people recovering from oral cancer surgery that used a free flap reconstruction. Thirty-six participants will use hydrogen water or plain water for oral care over 7 days. Researchers wi…
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Swallowing app aims to ease recovery after oral cancer surgery
Symptom relief Not yet recruitingThis study tests whether a mobile app with swallowing exercises can help people with oral cancer recover better after reconstructive surgery. About 72 adults in Taiwan will either get standard care or standard care plus the app. Researchers will measure swallowing function, anxie…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Can video calls replace clinic visits for palliative care?
Symptom relief Not yet recruitingThis study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…
Sponsor: Al Al Bayt University, Jordan • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Could a cold rinse soothe radiation mouth sores?
Symptom relief Not yet recruitingThis study will test whether rinsing with cold water (15-20°C) reduces mouth soreness and improves comfort compared to room-temperature water in 200 head and neck cancer patients undergoing radiotherapy. Participants will rinse four times daily for six weeks. The goal is to see i…
Sponsor: Chung Shan Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Leftover immunotherapy may boost chemo: new study investigates timing
Knowledge-focused Not yet recruitingThis study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…
Phase 4 • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Bacteria living in head and neck tumors: cause, consequence, or clue?
Knowledge-focused Not yet recruitingResearchers want to know whether the bacteria living in and around head and neck squamous cell carcinoma differ from those in healthy tissue. Adults scheduled for a standard throat examination because of suspected cancer give three extra samples during that procedure: tumor tissu…
Sponsor: Centre Hospitalier Sud Francilien • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Brain tumor or aneurysm first? study weighs the safer sequence
Knowledge-focused Not yet recruitingResearchers are observing patients in China who have both a tumor in the sellar region of the brain and an unruptured intracranial aneurysm. The study compares three approaches: removing the tumor before treating the aneurysm, treating the aneurysm before removing the tumor, or r…
Sponsor: Cheng sen • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Brain surgery safety: live signal monitoring may shield speech, movement, and sight
Knowledge-focused Not yet recruitingResearchers at Odense University Hospital are testing whether monitoring brain signals during tumor surgery can help preserve functions like movement, speech, and vision. The project includes a randomized trial comparing surgery with and without motor signal monitoring, plus obse…
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can a Nose-Route surgery remove skull base tumors more safely?
Knowledge-focused Not yet recruitingThis study looks at a surgical technique called the extended endoscopic endonasal approach (EEEA), which removes skull base lesions through the nose. The goal is to see how completely the tumor can be removed and how safe the procedure is. Adults with certain skull base tumors, s…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Immune cells may hold the key to faster recovery after facial surgery
Knowledge-focused Not yet recruitingThis study looks at whether changes in regulatory T cells (a type of immune cell) after facial reconstruction surgery can predict how quickly patients heal and how long they stay in the hospital. Researchers will collect blood samples from about 60 adults before, during, and afte…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Could a simple test spot oral cancer and gum disease early?
Knowledge-focused Not yet recruitingThis study aims to find biological markers in saliva, mouth rinse, blood, or tissue that could help identify and predict the course of oral cancer, gum disease, and tooth decay. Researchers will collect health information and samples from 4,000 adults with these conditions and he…
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a glowing drug light up head and neck tumors?
Knowledge-focused Not yet recruitingThis early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…
Early phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Olive oil and xylitol mouth rinse may shield cancer patients from painful mouth sores
Knowledge-focused Not yet recruitingThis study looks back at the medical records of 60 adults with head and neck cancer who received radiation therapy, with or without chemotherapy, and used a topical mouth rinse made from olive oil, betaine, and xylitol. The goal is to see how often severe mouth sores (oral mucosi…
Sponsor: Mucosa Innovations, S.L. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New workflow aims to prevent radiation errors in cancer treatment
Knowledge-focused Not yet recruitingThis trial tests a new communication workflow called CORRECT that helps radiologists and radiation oncologists work together more effectively when planning radiation therapy for lung and head-and-neck cancers. About 194 patients will be involved, and doctors will use a shared sys…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
New program aims to make cancer surgery safer for seniors
Knowledge-focused Not yet recruitingThis study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Could microplastics sabotage cancer treatment? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether tiny plastic particles released from medical masks during radiation therapy could affect treatment for head and neck cancer. Researchers will measure microplastic exposure and track patient outcomes to see if there is any link. The goal is to improve s…
Sponsor: University of Kragujevac • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
HIV and cancer: study seeks to uncover hidden risk factors
Knowledge-focused Not yet recruitingThis study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …
Sponsor: Shenzhen Third People's Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Saliva test may reveal hidden spread of oral cancer
Knowledge-focused Not yet recruitingThis study investigates whether substances in saliva, specifically interleukin-6 levels and certain gene variations, can indicate whether oral cancer has spread to lymph nodes in the neck. Researchers will collect saliva samples from adults with oral squamous cell carcinoma befor…
Sponsor: University of Pavia • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
AI could outshine standard tumor measurements to predict survival
Knowledge-focused Not yet recruitingThis study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Nose reconstruction or prosthesis? study aims to settle the debate
Knowledge-focused Not yet recruitingThis study compares two ways to rebuild the nose after partial or total loss: surgery using skin flaps, or a custom-made prosthetic nose (epithesis). Researchers will ask people who had either treatment at least one year ago to fill out a questionnaire about how their nose looks …
Sponsor: Hôpital NOVO • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Which intubation method works best for acromegaly patients?
Knowledge-focused Not yet recruitingThis study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…
Sponsor: Muzaffer GENCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Patient education may shorten hospital stays after pituitary surgery
Knowledge-focused Not yet recruitingThis study looks at whether giving patients clear, standardized instructions before and after pituitary surgery can improve their recovery. Researchers will compare hospital stay length, complication rates, and unplanned readmissions in 102 adults having elective surgery. The goa…
Sponsor: Uludag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI to predict cancer risk from gut bacteria and scans
Knowledge-focused Not yet recruitingThis study will collect data from 10,000 people undergoing upper endoscopy to build an AI model that predicts the risk of developing stomach or esophageal cancer. Researchers will combine information from endoscopy images, tissue samples, genetics, and gut bacteria. Participants …
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
New Real-Time imaging could make radiation therapy more precise
Knowledge-focused Not yet recruitingThis study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …
Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists map cell types in oral cancer to unlock early detection
Knowledge-focused Not yet recruitingThis study aims to understand the different cell types in oral cancer and pre-cancerous mouth lesions. Researchers will analyze tissue and blood samples from 150 participants to map gene activity and cell interactions. They will also test whether a simple brush sample can replace…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Does breakfast change how chemo works? new study investigates
Knowledge-focused Not yet recruitingThis early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…
Phase 1 • Sponsor: Health Hope Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
AI assistant for brain tumor surgery: a new training tool?
Knowledge-focused Not yet recruitingThis early-phase trial tests an artificial intelligence system that watches live video from pituitary tumor surgeries performed through the nose. The AI identifies anatomy, instruments, and surgical steps, displaying its analysis on tablets for the surgical team (not the lead sur…
Early phase 1 • Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Cancer Patients' samples to fuel Tomorrow's discoveries
Knowledge-focused Not yet recruitingThis study collects blood and tissue samples from 110 adults with advanced lung, head and neck, or mesothelioma cancer. The samples are stored in a biobank to help scientists study cancer genes and find better ways to predict treatment outcomes. Participants do not receive any ex…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study aims to understand laryngeal cancer Patients' recovery journey
Knowledge-focused Not yet recruitingThis study follows 120 people with laryngeal cancer to see how their quality of life, voice, swallowing, pain, and mood change before treatment and at 3, 6, and 12 months after. Researchers will use questionnaires to track these changes. The goal is to better understand recovery …
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Egyptian study aims to improve eye salvage in retinoblastoma
Knowledge-focused Not yet recruitingThis study will look back at the medical records of 150 children with retinoblastoma who received additional eye treatments after initial chemotherapy. The treatments include radioactive plaque therapy, freezing therapy, or laser therapy. The goal is to see how often each treatme…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
No-Needle patch could protect your smile during surgery
Knowledge-focused Not yet recruitingThis study tests a wireless patch that sticks to the face to monitor facial nerves during surgery, aiming to prevent nerve damage. It will be used alongside standard needle-based monitoring in 20 adults having parotid or facial surgery. Researchers will compare how well the patch…
Sponsor: Sheba Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Dye technique could spare neck surgery for head and neck cancer patients
Knowledge-focused Not yet recruitingThis study tests whether injecting two dyes around the tumor and into cancerous lymph nodes can help surgeons spot hidden cancer spread in head and neck cancer. Twenty adults with oral cavity or head and neck skin cancer will receive the dyes before surgery. The goal is to see if…
Phase 2 • Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists hunt for biological clues to Cancer-Related anxiety and depression
Knowledge-focused Not yet recruitingThis study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists hunt for clues to drug resistance in head and neck cancer
Knowledge-focused Not yet recruitingThis study will collect tumor and blood samples from 120 people with head and neck squamous cell carcinoma. Researchers will create mouse models from the samples and analyze molecular markers to understand resistance to standard therapies. The goal is to find new treatment target…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict which cancer patients struggle most with eating
Knowledge-focused Not yet recruitingThis study looks at how cancer and its treatments change the way people experience food, including taste, mouth health, and overall eating pleasure. Researchers will ask 180 adults with different cancers to fill out a detailed questionnaire about their eating habits and feelings.…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Brain tumor surgery could rewire your food cravings
Knowledge-focused Not yet recruitingThis study looks at how surgery for a rare brain tumor called craniopharyngioma might change what foods people like, especially fatty and sugary ones. Researchers will compare food preferences of 346 adults who had this surgery with two other groups: people who had a different pi…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Can a smart monitor prevent dangerous drops in blood pressure during oral cancer surgery?
Knowledge-focused Not yet recruitingThis study will test whether a device called the Hypotension Prediction Index (HPI) can help doctors keep blood pressure stable during oral cancer surgery. About 100 adults having oral cancer surgery with flap reconstruction will take part. Half of the surgeries will use the HPI …
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to find best treatment path for tough nasopharyngeal cancers
Knowledge-focused Not yet recruitingThis study looks at patients with a type of throat cancer (nasopharyngeal carcinoma) whose tumors did not shrink after two rounds of chemotherapy. It compares two different next steps: switching to a different chemotherapy combination before radiation, or going straight to radiat…
Sponsor: Fujian Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
World's first biobank for recurrent head and neck cancer launches
Knowledge-focused Not yet recruitingThis study creates a tissue bank and data registry for people with recurrent head and neck cancer. Researchers will collect samples and health information from thousands of participants to better understand the disease and find better treatments. The goal is to improve survival a…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can tongue power predict better eating after mouth cancer surgery?
Knowledge-focused Not yet recruitingThis study will measure tongue strength and biting force in 40 mouth cancer patients who use a special plate called an obturator to help them swallow. Researchers want to see how these measurements relate to what patients eat each day. The goal is to better understand how to impr…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a simple phone call after the ER get cancer patients treated faster?
Knowledge-focused Not yet recruitingThis pilot study will test whether trained community health navigators can help head and neck cancer patients get diagnosed and treated faster after an emergency room visit. The navigators will call or text patients to help with barriers like transportation, insurance, or housing…
Sponsor: University of Tennessee • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New tool aims to break the silence on oral cancer in black men
Knowledge-focused Not yet recruitingThis study tests a culturally tailored communication tool to help dentists discuss oral and pharyngeal cancers with Black men. Researchers will train dental providers and then pilot the tool in community settings with 50 Black men. The goal is to see if the tool improves comfort,…
Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New study aims to unlock clues in nasopharyngeal cancer
Knowledge-focused Not yet recruitingThis study looks for biological markers in people with nasopharyngeal carcinoma to help predict how the disease will progress and how well treatments might work. Researchers will analyze tissue samples from 60 newly diagnosed patients who have not had their cancer spread. The goa…
Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can scans and DNA predict cancer treatment success?
Knowledge-focused Not yet recruitingThis study aims to better predict how head and neck cancer responds to chemoradiotherapy. Researchers will use MRI, PET/CT scans, and blood/tumor DNA tests from 152 patients to build a combined prediction model. The goal is to identify which patients have a complete response with…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New tool to measure Cancer's financial toll tested in turkey
Knowledge-focused Not yet recruitingThis study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…
Sponsor: Akdeniz University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Gut check: could your microbiome predict fertility after immunotherapy?
Knowledge-focused Not yet recruitingThis observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New study aims to unlock immune secrets of nasopharyngeal cancer
Knowledge-focused Not yet recruitingThis study will look at tissue samples from 600 people with nasopharyngeal carcinoma to understand how the tumor's immune environment changes over time. The goal is to find markers that predict how well immunotherapy will work and to identify new treatment targets. Participants m…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Real-world test of adebrelimab combo for tough cancers
Knowledge-focused Not yet recruitingThis study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…
Sponsor: Tianjin First Central Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:13 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC